Former FDA attorney Mark Brown
This article was originally published in The Gray Sheet
Executive SummaryJoins D.C. law firm King & Spalding's food and drug practice this month. As associate chief counsel for enforcement in FDA's Office of the General Counsel since 1990, Brown became the agency's top litigator in device enforcement actions, most notably in the area of FDA's current good manufacturing practices regulations
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.